V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
1. The pharmacological profile of receptors activated by vasopressin (AVP) in freshly dissociated supraoptic magnocellular neurones was investigated using specific V1a- and V2-type AVP receptor agonists and antagonists. 2. In 97 % of AVP-responding neurones (1-3000 nM) V1a or V2 receptor type agonists (F-180 and dDAVP, respectively) elicited dose-dependent [Ca2+]i transients that were suppressed by removal of external Ca2+. 3. The [Ca2+]i response induced by 1 microM F-180 or dDAVP was selectively blocked by 10 nM of V1a and V2 antagonists (SR 49059 and SR 121463A, respectively). The response to V1a agonist was maintained in the presence of the V2 antagonist, and the V2 agonist-induced response persisted in the presence of the V1a antagonist. 4. The [Ca2+]i response induced by 1 microM AVP was partially (61 %) blocked by 10 nM SR 121463A. This blockade was increased by a further 31 % with the addition of 10 nM SR 49059. Similarly, the AVP-induced response was partially (47 %) decreased by SR 49059, and a further inhibition of 33 % was achieved in the presence of SR 121463A. 5. We demonstrate that AVP acts on the magnocellular neurones via two distinct types of AVP receptors that exhibit the pharmacological profiles of V1a and V2 types. However, since V2 receptor mRNA is not expressed in the supraoptic nucleus (SON), and since V1b receptor transcripts are observed in the SON, we propose that the V2 receptor agonist and antagonist act on a 'V2-like' receptor or a new type of AVP receptor that remains to be elucidated. The possibility that V2 ligands act on the V1b receptor cannot be excluded.
Gouzénes
L
L
CNRS UPR-9055, Biologie des Neurones Endocrines, CCIPE, 141 rue de la Cardonille, F-34094 Montpellier cedex 05, France.
Sabatier
N
N
Richard
P
P
Moos
F C
FC
Dayanithi
G
G
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017483:Receptors, Vasopressin / Q000235:genetics / Q000502:physiology*; D013141:Spiro Compounds / Q000494:pharmacology; D013495:Supraoptic Nucleus / Q000166:cytology / Q000502:physiology*; D014158:Transcription, Genetic; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014667:Vasopressins
D065092:Antidiuretic Hormone Receptor Antagonists; C110660:F-180 vasoconstrictor peptide; D007211:Indoles; D009025:Morpholines; D011759:Pyrrolidines; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D001127:Arginine Vasopressin; C103281:satavaptan; C082134:relcovaptan; D003894:Deamino Arginine Vasopressin; D002118:Calcium